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INTRODUCTION
Several recent studies have reported a 40–50% lower risk of
colorectal cancer in people who are continuously taking aspirin or
other nonsteroidal anti-inflammatory drugs (NSAIDs) (Thun et al,
1991; 1993; Marnett, 1992; 1995; Giovannucci et al, 1994; 1995).
The mechanism by which NSAIDs prevent colorectal carcino-
genesis is not clear, but one possibility involves inhibition of
cyclooxygenase (COX).
COX is a key enzyme in the conversion of arachidonic acid to
prostaglandins, and two isoforms of COX, namely COX-1 and
COX-2, have been identified. COX-1 is constitutively expressed in
most cells and tissues, including normal intestinal and gastric
mucosa (Williams and DuBois, 1996), and is considered to be
involved in various physiological functions such as cytoprotection
of the gastric mucosa. On the other hand, COX-2 is induced by a
variety of agents including cytokines, hormones, growth factors,
and tumour promoters, and its expression is elevated in inflamma-
tory cells and sites of inflammation (Kujubu et al, 1991; O’Banion
et al, 1991; Jones et al, 1993; DuBois et al, 1994; Xie and
Hershman, 1995). Recently multiple studies have shown that COX-
2 is expressed at high levels in 80–90% of colorectal adenocarci-
nomas (Eberhart et al, 1994; Kargman et al, 1995; Sano et al,
1995), and selective inhibition of COX-2 reduces colorectal
tumourigenesis in different models of carcinogenesis (Oshima et al,
1996; Reddy et al, 1996; Kawamori et al, 1998). Thus, COX-2 has
been thought to play a causal role in colorectal tumorigenesis.
Furthermore, it has recently been reported that a human colon
cancer cell line transfected with a COX-2 expression vector
acquired increased invasiveness with activation of matrix metallo-
proteinase (Tsuji et al, 1997). We also have shown that a selective
COX-2 inhibitor, JTE-522, suppressed haematogenous metastasis
of colon cancer in mice (Tomozawa et al, 1999). These findings
suggest that COX-2 might be involved in not only tumorigenesis
but also cancer metastasis.
Here, we examined COX-2 expression in primary advanced
colorectal carcinoma tissue using immunohistochemistry and its
correlation with clinicopathological features.
MATERIALS AND METHODS
Patient samples
Specimens from 63 patients with advanced colorectal cancer
without haematogenous metastasis receiving radical surgical treat-
ment at the Department of Surgical Oncology, the University of
Tokyo, in the period 1990–1994, were evaluated. In all these
patients, the depth of tumour invasion was proper muscle (mp) or
subserosa (ss). The median follow-up period was 60 months
(range 6–98).
Immunohistochemistry
Tissue samples were fixed with 10% formaldehyde in phosphate-
buffered saline (PBS), embedded in paraffin, and cut into
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3 mm-thick sections. The sections were deparaffinized, hydrated
through xylene and alcohol, and microwaved in Target Retrieval
Solution (DAKO Japan, Kyoto, Japan) for 15 min. After washing
three times in PBS, endogenous peroxidase was blocked by
immersion in 3% hydrogen peroxide for 30 min at room tempera-
ture. After washing three times in PBS, non-specific binding was
blocked by incubation with 10% normal goat serum for 30 min.
Then, rabbit polyclonal antibody specific for human COX-2 (IBL,
Gunma, Japan) diluted 40-fold with PBS was applied and sections
were incubated at 4°C overnight. After washing again three times
with PBS, the specimens were incubated with biotinylated anti-
rabbit immunoglobulin G (IgG) for 30 min at room temperature.
After washing three times in PBS, they were incubated with avidin
and biotinylated horseradish peroxidase complex, followed by
three washes with PBS. Then, the immune complex was visualized
by immersing the slides in 0.2 mg ml–1 diaminobenzine and 0.03%
H2O2 in PBS for 1.5 min. The sections were then counterstained
with haematoxylin and mounted. Non-immunized rabbit serum
was used as the negative control. As an alternative control, all the
63 specimens were simultaneously stained for COX-1 using a
specific rabbit polyclonal antibody (IBL, Gunma, Japan), and
exactly the same methodology applied for COX-2 immuno-
staining.
Evaluation of COX-2 immunostaining
The specimens immunostained for COX-2 were evaluated
independently by two blinded investigators. According to the
intensity and extent of positive reaction of tumour cells, the
patients were divided into grades 1–4. Grades 1 and 2 were classi-
fied as low-COX-2 group, and grades 3 and 4 as high-COX-2
group. In brief, the reactions of normal colonic epithelium and
stromal mononuclear cells in the colonic mucosa distant from
cancer tissue were used as the internal built-in controls. Normal
colonic epithelium showed a very weak but diffuse staining
pattern, whereas mononuclear cells stained strongly.
Immunostaining of cancer tissues was stronger than the normal
epithelium in all cases. Therefore, the intensity of staining was
graded on a scale of 1–4 using mononuclear cells as the reference.
Grades 1 and 2 were cases with COX-2 expression weaker than,
grade 3 similar to, and grade 4 stronger than, mononuclear cells.
The extent of immunostaining was diffuse in all cases, and
heterogeneity was observed in only a few cases.
Statistical analysis
The correlation between patient’s age or tumour size and COX-2
expression was studied using Student’s t-test. The other clinico-
pathological features were analysed in relation to COX-2 expres-
sion by chi-squared test. The Kaplan–Meier method was used to
estimate the survival rates without tumour recurrence, and the
log-rank test was used to compare survival rates in the two groups.
To determine significant prognostic factors, multivariate analysis
was performed using the Cox proportional hazards modelling of
factors potentially related to disease-free survival. Differences
were considered statistically significant at P < 0.05.
RESULTS
Immunostaining
In all cases, COX-2 expression was predominantly localized in
tumour cells, whereas some stromal cells, endothelial cells, and
colonic normal mucosa adjacent to the cancer tissue stained
weakly. In cancer cells, COX-2 expression was observed mainly in
the cytoplasm and nuclear envelope. In general, normal colonic
mucosa distant from the cancer tissue showed little or no COX-2
expression (Figure 1).
As described in Materials and methods, the patients were
divided into low- and high-COX-2 groups according to the grade
and extent of COX-2 expression. High COX-2 expression was
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Figure 1 COX-2 immunostaining (A, B, F, G, H, I, J). Negative control (C).
COX-1 immunostaining (D, E). (A) (´ 25) A representative case of colon
cancer tissue (grade 3). COX-2 expression is observed in the cytoplasm and
in the nuclear envelope of the tumour cells, and some stromal cells are
stained. The extent of immunostaining of the tumour is diffuse. (B) (´ 25) A
large field of view encompassing tumour and adjacent tissue.
Immunostaining of the cancer tissue is stronger than the normal epithelium.
(C) (´ 10) A negative control by non-immunized rabbit serum. (D and E)
(´ 50) COX-1 immunostaining of colorectal cancer and normal colonic
mucosa, respectively. COX-1 expression is restricted to some stromal cells
and its expression is observed in neither the cancer nor the normal
epithelium. (F) (´ 50), (G, H and I) (´ 100) Tumours classified as grade 4, 3,
2, and 1, respectively. (J) (´ 100) Normal colonic mucosa and mononuclear
cells that we used as internal built-in controls. Normal colonic epithelium
shows a very weak but diffuse staining pattern, whereas mononuclear cells
are stained strongly326 S Tomozawa et al
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observed in 13 (21%) cases (grade 3 in 11 (18%) and grade 4 in 2
(3%)). Low COX-2 expression was observed in 50 (79%) cases
(grade 1 in 20 (32%) and grade 2 in 30 (47%)).
In all cases COX-1 expression was restricted to some stromal
cells and its expression was observed in neither the cancer nor the
normal epithelium (Figure 1).
Relation between COX-2 expression and
clinicopathological features
In Table 1, the association between COX-2 expression and the
clinicopathological features is shown. There was no significant
correlation between COX-2 expression and age, sex, tumour size,
tumour location, histological type, depth of invasion, lymphatic or
venous invasion, lymph-node metastasis and Dukes’ classifica-
tion. However, high COX-2 expression was strongly correlated
with tumour recurrence, especially haematogenous metastasis
(P = 0.005).
Table 1 Correlation between COX-2 expression and clinicopathological features
Variable High-COX-2 Low-COX-2 P value
Number of cases 13 50
Age (yrs) 61 ± 9 61 ± 11 0.94b
Sex Male 7 31 0.59a
Female 6 19
Tumour size (mm) 41 ± 13 41 ± 25 0.98b
Tumour location Colon 5 31 0.13a
Rectum 8 19
Histological type Well diff. Adenoca. 8 39 0.22a
Moderately or poorly 5 11
diff.adenoca.
Depth mp a 25 0.22a
ss (a1)9 2 5
ly + 4 13 0.73a
–9 3 7
v + 6 15 0.27a
–7 3 5
LN + 4 10 0.41a
–9 4 0
Dukes’ classification A and B 4 10 0.41a
C9 4 0
Recurrence + 6 6 0.005a
–7 4 4
Recurence by + 5 4 0.005a
haematogenous metastasis – 8 46
ly: lymphatic invasion; v: venous invasion; LN: lymph-node metastasis. Tumour size: maximal diameter; aChi-sq; bStudent’s t-test.
Table 2 Results of multivariate analysis of possible prognostic factors related to disease-free survival by Cox proportional hazards
model
Variable Hazard ratio (95% CI) Unfavourable/favourable P value
Age (yrs) 0.940 (0.863–1.023) 0.1538
Sex 0.382 (0.084–1.746) Male/Female 0.2148
Histological type 1.118 (0.813–1.539) Poorly or moderately/Well 0.4197
Tumour size (mm) 1.020 (0.991–1.050) 0.1795
ly 2.215 (0.542–9.054) Positive/Negative 0.2681
v 2.134 (0.633–7.189) Positive/Negative 0.2213
Dukes’ stage 4.222 (0.999–17.835) C/A and B 0.0501
COX-2 expression 10.086 (1.971–51.612) High/Low 0.0055
Figure 2 Kaplan–Meier disease-free survival curves of patients in high-
COX-2 (n) and low-COX-2 (l) groups. A statistically significant difference
was observed between the two groups (P = 0.0051)COX-2 overexpression and recurrence of colorectal cancer 327
British Journal of Cancer (2000)  83(3), 324–328 © 2000 Cancer Research Campaign
Correlation of COX-2 expression with disease-free
survival
The survival rate without tumour recurrence for high- and low-
COX-2 groups was assessed by the Kaplan–Meier method and
compared by log-rank test (Figure 2). The disease-free survival
rate was significantly different between the two groups
(P = 0.0051). Table 2 shows the results of multivariate analysis for
the 63 patients. Among the 8 potentially prognostic factors (age,
sex, histological type, tumour size, lymphatic invasion, venous
invasion, Dukes’ stage, and COX-2 expression), COX-2 expres-
sion was recognized as the only independent significant factor
related to disease-free survival (P = 0.0055).
DISCUSSION
So far COX-2 has been thought to play a causal role in colorectal
tumorigenesis. A null mutation of COX-2 caused a marked reduc-
tion in the number and size of intestinal polyps in a murine model
of FAP (familial adenomatous polyposis) APCD716 knockout mice
(Oshima et al, 1996). In a separate study, SC-58635, a selective
inhibitor of COX-2, reduced the formation of aberrant crypt foci
and inhibited both the incidence and multiplicity of colon tumours
in the intestines of azoxymethanetreated rats (Reddy et al, 1996;
Kawamori et al, 1998). Recently, it has been reported that in nude
mice, selective inhibition of COX-2 by SC-58125 reduced growth
of a human colon cancer cell line, HCA-7, which expresses a high
level of COX-2, but it did not reduce the growth of
HCT-116 cells, which lack COX-2 protein (Sheng et al, 1997). In
addition, it has been shown that COX-2 level was significantly
higher in colorectal tumours with larger size and in those with
deeper invasion (Fujita et al, 1998). These results suggest an
important role of COX-2 in colorectal tumourigenesis and growth.
Another recent report demonstrated that human colon cancer
(Caco-2) cells permanently transfected with a COX-2 expression
vector acquired increased invasiveness, with increased activation
of matrix metalloproteinase-2 (MMP-2) and increased RNA
level of membrane-type matrix metalloproteinase-1 (MT-MMP-1)
(Tsuji et al, 1997). In a previous study we have also demonstrated
that a selective COX-2 inhibitor, JTE-522, prevented haematoge-
nous metastasis of colon cancer in mice (Tomozawa et al, 1999).
These results suggest that COX-2 increases the metastatic poten-
tial of colorectal cancer cells.
In the present study, using immunohistochemistry, we examined
COX-2 expression in advanced human colorectal carcinomas and
demonstrated that COX-2 overexpression, although not correlated
with the other clinicopathological features, was significantly
associated with tumour recurrence, especially haematogenous
metastasis.
Contrary to our results, in a recent study (Fujita et al, 1998),
elevated COX-2 levels were not correlated with metastasis. In that
study, however, only patients with a very short follow-up period
were included, and consequently only synchronous metastasis
could be evaluated. In the present study, we used samples from
patients who received curative resection and had a longer follow-
up (median 60 months), and consequently more reliable data on
the correlation of COX-2 expression and the development of
haematogenous metastasis could be obtained. Moreover, different
from the previous report, in which COX-2 expression was
investigated at the mRNA level and expressed as the COX-2 &
COX-1 ratio, we investigated it at the protein level. These facts
may explain the discrepancy between the two studies.
Haematogenous metastasis of colorectal cancer develops
through a complicated process: cancer cells detach from the
primary site and reach the vasculature by proteolytic cleavage of
the surrounding interstitial tissues. Then the cells reach the
secondary sites by adhesion to and transmigration through the
endothelial cell layer and invasion of the secondary organ, and
they proliferate at secondary sites by induction of angiogenesis
(Liotta et al, 1986). From our data, COX-2 overexpression in
colorectal cancer did not correlate with venous permeation,
but with increased haematogenous metastasis formation. COX-2
expression was recognized as the only independent significant
factor related to disease-free survival. Therefore, COX-2 may
affect not only the proliferative and invasive properties but also
the adhesion of colorectal cancer cells to extracellular matrix
(ECM) protein or endothelial cells. It has been reported that rat
intestinal epithelial (RIE) cells permanently transfected with a
COX-2 expression vector oriented in the sense (RIE-S) demon-
strated increased adhesion to ECM and expressed undetectable
E-cadherin, which is involved in cell–cell adhesion (Tsujii et al,
1995). However, more studies are necessary to elucidate the effect
of COX-2 on adhesion of cancer cells to ECM or endothelium, and
such studies are ongoing in our laboratory.
Another possible role of COX-2 in the development of
haematogenous metastasis is promotion of angiogenesis. Tumour
growth and metastasis require the development of new vessels, i.e.
angiogenesis (Folkman, 1990; Mahadevan and Hart, 1990; Horak
et al, 1992). In a recent report, COX-2 was reported to modulate
the production of angiogenic factors by colon cancer cells, while
COX-1 was associated with angiogenesis regulation in endothelial
cells (Tsujii et al, 1998).
Furthermore, COX-2 expression has recently been reported to
be up-regulated not only in colorectal neoplasms but also in
gastric, breast, oesophageal, pancreatic and lung carcinoma
(Ristimaki et al, 1997; Hida et al, 1998; Hwang et al, 1998;
Zimmermann et al, 1999; Tucker et al, 1999), and COX-2 over-
expression enhanced lymphatic invasion and metastasis of human
gastric carcinoma (Murata et al, 1999). And another recent report
has shown that elevated COX-2 expression has a poorer prog-
nostic significance in early-stage primary resected lung adeno-
carcinoma (Achiwa et al, 1999). These findings suggest that
COX-2 may provide a new therapeutic target for several kinds of
neoplasms.
To our knowledge, this is the first report on the correlation
between COX-2 overexpression and recurrence of colorectal
cancer, especially haematogenous metastasis, and this fact suggest
that selective COX-2 inhibitors can be useful chemopreventive
agents not only for tumorigenesis but also for haematogenous
metastasis of colorectal cancer.
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